Another phase II clinical trial investigated the impact of durvalumab in combination with tremelimumab in NSCLC patients resistant to anti-PD-1, with 10% overall response rate of and 30% disease control rate (206). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.